Physician knowledge, practice patterns, and barriers encountered regarding guideline‐concordant use of bone modifying agents for prostate cancer
Abstract
Guidelines recommend bone‐modifying agents (BMAs) for patients with castrate‐resistant prostate cancer (CRPC) and bone metastasis, but not for castrate‐sensitive prostate cancer (CSPC). Physicians beliefs and practices regarding BMA therapy are poorly understood.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 16, 2023
- Source ID
- 10.1002/pros.24636
Entities
People
- Aaron Mitchell
- Andrew Salner
- Azeez Farooki
- Jamie S. Ostroff
- Michael J. Morris
- Paul Palyca
- Sonia Persaud
- Susan Chimonas
Organizations
- Congressionally Directed Medical Research Programs
- Memorial Sloan Kettering Cancer Center